|Slideshows|August 4, 2017

8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis

Author(s)Ruby S. Grewal, MD, Tony P. George, MD, FRCPC

The authors compare the clinical features of idiopathic psychosis (eg, schizophrenia) with cannabis-induced psychosis.

View the slides in PDF format.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Connecting REM Sleep and Substance Use Vulnerability

ByColleen McClung, PhD

June 19th 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

ByMichael Murphy, MD, PhD,Allison Nelson-Eliot, LICSW

June 18th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Transcranial Direct Current Stimulation to Enhance Brain Activity: Applicability for Schizophrenia

ByTony Cunningham, PhD

June 17th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

8 Distinguishing Features of Primary Psychosis Versus Cannabis-Induced Psychosis

Related Content

Connecting REM Sleep and Substance Use Vulnerability

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Assessment of Suicide Risk in Individuals With Schizophrenia

Transcranial Direct Current Stimulation to Enhance Brain Activity: Applicability for Schizophrenia

Latest CME

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Sex Differences, Sleep Problems, and Psychological Well-Being in Older Adults

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Zolpidem: Restoring Sleep and Slowing Alzheimer Disease Progression

GABA Deficits and Sleep Disruption in Early Alzheimer Disease